Clindamycin

May be taken with or without food. Cap: Take w/ a full glass of water to avoid oesophageal irritation. Granules for oral soln: Dissolve in water & shake well before use.

Hypersensitivity. Topical or vaginal: History of inflammatory bowel disease, regional enteritis, or ulcerative or antibiotic-associated colitis.

Patient with atopy, history of gastrointestinal disease (e.g. colitis). Not indicated for the treatment of meningitis. Renal and moderate to severe hepatic impairment. Neonates, children, and elderly. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor CBC, LFTs, renal function (periodically during prolonged treatment). Asses for changes in bowel frequency; signs of colitis and resolution of symptoms.

Significant: Superinfection (particularly yeasts), acute kidney injury (including acute renal failure). Blood and lymphatic system disorders: Agranulocytosis, neutropenia, thrombocytopenia, leucopenia, eosinophilia. Cardiac disorders: Rarely, cardiopulmonary arrest (rapid IV inj). Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dysgeusia. General disorders and administration site conditions: Pain and/or abscess at the inj site. Investigations: Abnormal LFTs. Nervous system disorders: Headache, dizziness. Renal and urinary disorders: UTI, glycosuria, proteinuria (vaginal). Reproductive system and breast disorders: Vulvovaginal candidiasis, pain, or disorder (vaginal). Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus. Skin dryness or oiliness (topical). Vascular disorders: Thrombophlebitis (IV). Rarely, hypotension (rapid IV inj).
Potentially Fatal: Clostridioides difficile-associated diarrhoea (CDAD), pseudomembranous colitis; severe cutaneous adverse reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).

May enhance the action of neuromuscular blocking agents. May increase coagulation tests (e.g. prothrombin time, INR) and risk of bleeding with vitamin K antagonists (e.g. warfarin, acenocoumarol, fluindione). Increased plasma concentrations with CYP3A4 and CYP3A5 inhibitors. Reduced plasma concentrations with CYP3A4 and CYP3A5 inducers.

Acne Treatment Preparations / Other Antibiotics / Preparations for Vaginal Conditions / Topical Antibiotics

J01FF01 - clindamycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections.
G01AA10 - clindamycin ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
D10AF01 - clindamycin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.